McRae Capital Management’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-121,435
| Closed | -$9.79M | – | 98 |
|
|
2023
Q1 | $9.79M | Buy |
121,435
+1,300
| +1% | +$106K | 2.82% | 15 |
|
|
2022
Q4 | $9.34M | Sell |
120,135
-8,920
| -7% | -$723K | 2.73% | 18 |
|
|
2022
Q3 | $10.4M | Sell |
129,055
-896
| -0.7% | -$80.5K | 3.17% | 15 |
|
|
2022
Q2 | $11.7M | Sell |
129,951
-185
| -0.1% | -$18.7K | 3.17% | 12 |
|
|
2022
Q1 | $14.4M | Buy |
130,136
+1,595
| +1% | +$169K | 3.26% | 10 |
|
|
2021
Q4 | $13.3M | Buy |
128,541
+7,100
| +6% | +$822K | 2.77% | 15 |
|
|
2021
Q3 | $15.2M | Sell |
121,441
-775
| -0.6% | -$100K | 3.35% | 10 |
|
|
2021
Q2 | $15.2M | Buy |
122,216
+579
| +0.5% | +$72.7K | 3.47% | 10 |
|
|
2021
Q1 | $14.4M | Buy |
121,637
+4,009
| +3% | +$470K | 3.56% | 9 |
|
|
2020
Q4 | $13.8M | Sell |
117,628
-487
| -0.4% | -$53.6K | 3.95% | 6 |
|
|
2020
Q3 | $12.3M | Buy |
118,115
+1,106
| +0.9% | +$111K | 4.11% | 5 |
|
|
2020
Q2 | $10.7M | Buy |
117,009
+1,530
| +1% | +$147K | 4.02% | 6 |
|
|
2020
Q1 | $10.4M | Buy |
115,479
+550
| +0.5% | +$58.5K | 5.08% | 3 |
|
|
2019
Q4 | $13M | Sell |
114,929
-196
| -0.2% | -$21.5K | 4.8% | 2 |
|
|
2019
Q3 | $12.5M | Sell |
115,125
-4,545
| -4% | -$474K | 4.87% | 2 |
|
|
2019
Q2 | $11.7M | Buy |
119,670
+3,630
| +3% | +$331K | 4.66% | 3 |
|
|
2019
Q1 | $10.6M | Buy |
116,040
+785
| +0.7% | +$70.3K | 4.4% | 5 |
|
|
2018
Q4 | $10.5M | Buy |
115,255
+905
| +0.8% | +$84.6K | 5.39% | 3 |
|
|
2018
Q3 | $11.2M | Sell |
114,350
-705
| -0.6% | -$65.2K | 4.77% | 3 |
|
|
2018
Q2 | $9.85M | Buy |
115,055
+519
| +0.5% | +$43.4K | 4.12% | 6 |
|
|
2018
Q1 | $9.19M | Sell |
114,536
-3,410
| -3% | -$281K | 4.15% | 6 |
|
|
2017
Q4 | $9.52M | Sell |
117,946
-819
| -0.7% | -$65.6K | 4.02% | 9 |
|
|
2017
Q3 | $9.24M | Buy |
118,765
+540
| +0.5% | +$44.8K | 3.97% | 6 |
|
|
2017
Q2 | $10.5M | Buy |
118,225
+4,431
| +4% | +$374K | 4.26% | 4 |
|
|
2017
Q1 | $9.17M | Buy |
113,794
+3,855
| +4% | +$301K | 3.78% | 6 |
|
|
2016
Q4 | $7.83M | Buy |
109,939
+5,016
| +5% | +$394K | 3.46% | 10 |
|
|
2016
Q3 | $9.06M | Sell |
104,923
-2,456
| -2% | -$214K | 4.12% | 4 |
|
|
2016
Q2 | $9.32M | Buy |
107,379
+9,185
| +9% | +$743K | 4.31% | 3 |
|
|
2016
Q1 | $7.37M | Buy |
98,194
+5,183
| +6% | +$390K | 3.29% | 14 |
|
|
2015
Q4 | $7.15M | Sell |
93,011
-2,350
| -2% | -$177K | 3.43% | 11 |
|
|
2015
Q3 | $6.38M | Sell |
95,361
-1,850
| -2% | -$136K | 3.25% | 13 |
|
|
2015
Q2 | $7.2M | Sell |
97,211
-900
| -0.9% | -$68.8K | 3.36% | 11 |
|
|
2015
Q1 | $7.65M | Sell |
98,111
-2,300
| -2% | -$174K | 3.53% | 11 |
|
|
2014
Q4 | $7.25M | Sell |
100,411
-2,289
| -2% | -$159K | 3.35% | 12 |
|
|
2014
Q3 | $6.36M | Sell |
102,700
-4,245
| -4% | -$270K | 3.09% | 17 |
|
|
2014
Q2 | $6.82M | Sell |
106,945
-1,850
| -2% | -$112K | 3.29% | 13 |
|
|
2014
Q1 | $6.7M | Sell |
108,795
-1,400
| -1% | -$81.5K | 3.38% | 12 |
|
|
2013
Q4 | $6.32M | Buy |
110,195
+250
| +0.2% | +$14.2K | 3.25% | 13 |
|
|
2013
Q3 | $5.86M | Buy |
109,945
+600
| +0.5% | +$32.3K | 3.24% | 14 |
|
|
2013
Q2 | $5.63M | Buy |
+109,345
| New | +$5.41M | 3.28% | 14 |
|
Other funds holding MDT
McRae Capital Management's MDT Position: Q2 2023 in Review
McRae Capital Management sold out of Medtronic (MDT) in Q2 2023, closing a stake of 121,435 shares — an estimated $9.79M sold.
McRae Capital Management first reported a position in MDT in Q2 2013 and held it in 40 quarters. The position peaked at $15.2M in Q3 2021. 2,056 funds tracked by Wall St. Rank hold MDT as of Q2 2023.
- McRae Capital Management reported no remaining Medtronic position as of Q2 2023 after selling out during the quarter.
- McRae Capital Management sold 121,435 Medtronic shares in Q2 2023, an estimated $9.79M.
- McRae Capital Management first reported a position in Medtronic in Q2 2013 and held it in 40 quarters.
- McRae Capital Management's Medtronic position peaked at $15.2M in Q3 2021.
- 2,056 funds tracked by Wall St. Rank held Medtronic as of Q2 2023.
Based on McRae Capital Management's 13F filing for Q2 2023, filed 21 Jul 2023.